FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC - The Cancer Letter
Immediate change: card charged prorated amount based on current subscription level. Options: OK or Cancel.
Reference News
FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC
Effective immediately, card will be charged a prorated amount based on existing subscription level. Options: OK or Cancel.
FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC - The Cancer Letter
Immediate change: card charged prorated amount based on current subscription level. Options: OK or Cancel.